ArticleNature biomedical engineering2022
Conditional immortalization of human atrial myocytes for the generation of in vitro models of atrial fibrillation.
Article in Nature biomedical engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Pooled it
- Smart Optogenetics for Real-Time Automated Control of Cardiac Electrical Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cardiac differentiation roadmap for analysis of plasticity and balanced lineage commitment.Stem cell reports · 2025Article
- Analysing complex excitation patterns in cardiac tissue using wave event networks.Frontiers in network physiology · 2025Article
- Single-cell RNA sequencing reveals the contribution of smooth muscle cells and endothelial cells to fibrosis in human atrial tissue with atrial fibrillation.Molecular medicine (Cambridge, Mass.) · 2024Article
- Analysis of complex excitation patterns using Feynman-like diagrams.Scientific reports · 2024Article
- Identification of the optimal reference genes for atrial fibrillation model established by iPSC-derived atrial myocytes.BMC genomics · 2024Article
- Advances in 3D Bioprinted Cardiac Tissue Using Stem Cell-Derived Cardiomyocytes.Stem cells translational medicine · 2024Review
- Opto-electronic feedback control of membrane potential for real-time control of action potentials.Cell reports methods · 2023Article
- Towards Improved HumanBiomedicines · 2023Review
- Harnessing developmental cues for cardiomyocyte production.Development (Cambridge, England) · 2023Review
- Diversity of cells and signals in the cardiovascular system.The Journal of physiology · 2023Article
- Non-Trivial Dynamics in the FizHugh-Rinzel Model and Non-Homogeneous Oscillatory-Excitable Reaction-Diffusions Systems.Biology · 2023Article
- Adiposity-associated atrial fibrillation: molecular determinants, mechanisms, and clinical significance.Cardiovascular research · 2023Review
- Research Progress towards the Effects of Fatty Acids on the Differentiation and Maturation of Human Induced Pluripotent Stem Cells into Cardiomyocytes.Reviews in cardiovascular medicine · 2023Review
- Grapefruit Flavonoid Naringenin Sex-Dependently Modulates Action Potential in an In Silico Human Ventricular Cardiomyocyte Model.Antioxidants (Basel, Switzerland) · 2022Article
- Improved Atrial Differentiation of Human Pluripotent Stem Cells by Activation of Retinoic Acid Receptor Alpha (RARα).Journal of personalized medicine · 2022Article
- Article
- Article
- How Functional Genomics Can Keep Pace With VUS Identification.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of a scalable and robust source of well-differentiated human atrial myocytes constrains the development of in vitro models of atrial fibrillation (AF). Here we show that fully functional atrial myocytes can be generated and expanded one-quadrillion-fold via a conditional cell-immortalization method relying on lentiviral vectors and the doxycycline-controlled expression of a recombinant viral oncogene in human foetal atrial myocytes, and that the immortalized cells can be used to generate in vitro models of AF. The method generated 15 monoclonal cell lines with molecular, cellular and electrophysiological properties resembling those of primary atrial myocytes. Multicellular in vitro models of AF generated using the immortalized atrial myocytes displayed fibrillatory activity (with activation frequencies of 6-8 Hz, consistent with the clinical manifestation of AF), which could be terminated by the administration of clinically approved antiarrhythmic drugs. The conditional cell-immortalization method could be used to generate functional cell lines from other human parenchymal cells, for the development of in vitro models of human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.